[ad_1]
The government began evaluating the possibility of conducting a Covid-19 vaccination “D-day” across the country on January 23.
According to reports made to CNN, this optimistic scenario takes into account the possibility that 2 million doses of the immunizer developed by the British pharmaceutical company AstraZeneca in partnership with the University of Oxford will arrive at Fiocruz between the 15th and 20th of this month. This first batch would come from the Serium Institute, India, responsible for the manufacture of the product.
A CNN He discovered that the idea that is being discussed in the Ministry of Health is to start vaccination by shelters for the elderly throughout the country on the same day.
The government’s expectation is to also receive supplies of the Oxford vaccine by the 15th. Therefore, Fiocruz could begin production in the country at the end of this month.
Watch and read too
South African coronavirus strain is more dangerous than British strain, minister says
São Paulo identifies two cases of the English variant of the coronavirus in Brazil
What is known about the pharmacist who damaged the doses of Covid-19 vaccine
US Prepares for Total Healthcare Collapse After Covid-19 Rise
According to projections that have reached health, the Brazilian laboratory has the capacity to produce 15 million doses per month.
The idea is to start with 1 million a week and gradually increase until you reach the maximum level of production.
This Monday (4), Fiocruz and Anvisa (National Health Agency) met to attend to the request for emergency use of the vaccine in Brazil.
During the meeting, Fiocruz presented data on the Oxford immunizer, but the agency said in a note to expect information showing that the Indian product is similar to the one made in the United Kingdom.
to the National Health Surveillance Agency (Anvisa), but the procedure was not considered sufficient for the emergency approval of the immunizer.
The basis still depends on the data to be provided by the Serium Institute, India, responsible for the manufacture of the product.
“In more technical terms, the objective of this evaluation is to guarantee equivalence in terms of the immunogenicity response, that is, the ability of the vaccine to activate an immune response or reaction, such as the development of specific antibodies, T-cell responses , allergic or anaphylactic reactions, ”said Anvisa.
Also according to the agency, if there are differences between the products in the UK and India, “comparability studies should be done” to show that the vaccines are equivalent.
If there is a difference between the products, “comparability” studies should be carried out to show that both are at least equivalent.
